Survival Benefits of Neoadjuvant Systemic Chemotherapy in Muscle Invasive Bladder Cancer

Not yet recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

November 4, 2025

Primary Completion Date

November 4, 2026

Study Completion Date

December 1, 2026

Conditions

Bladder Urothelial Carcinoma

Interventions

DRUG

Chemotherapy with platine

medical records that patients received neoadjuvant systemic chemotherapy platine based

All Listed Sponsors

lead

Sara Mahmoud Ahmed Mahmoud

OTHER

NCT06727214 - Survival Benefits of Neoadjuvant Systemic Chemotherapy in Muscle Invasive Bladder Cancer | Biotech Hunter | Biotech Hunter